颠倒
间充质干细胞
耐火材料(行星科学)
哮喘
医学
气道
干细胞
干细胞疗法
癌症研究
免疫学
细胞生物学
病理
生物
材料科学
外科
天体生物学
复合材料
作者
Xing-Yue He,Meng‐Meng Han,Yuchen Zhao,Tang Ling,Yi Wang,Lei Xing,Ning Wei,Wei Wang,Guangji Wang,Fang Zhou,Jee–Heon Jeong,Hu‐Lin Jiang
出处
期刊:PubMed
日期:2024-10-28
标识
DOI:10.1016/j.jconrel.2024.10.056
摘要
In the development of asthma, subepithelial fibrosis and vascular proliferation cause airway remodeling and narrowing, leading to disease deterioration and respiratory failure. In the clinic, the treatment of asthma was aimed at reducing the frequency of acute asthma attacks through inhaled corticosteroids (ICSs). However, ICSs cannot prevent the progression into refractory asthma due to the formation of airway remodeling mainly by subepithelial fibrosis and angiogenesis surrounding the tracheal lumen. Herein, we constructed surface-engineered mesenchymal stem cells (MSCs/PVLA) via the bioconjugation of MSCs and reactive oxygen species-responsive polymeric micelles loaded with vactosertib (VST) and linifanib (LFN) for treating refractory asthma through reversing airway remodeling. MSCs/PVLA migrated to the tracheal lumen due to the inflammation tropism of MSCs, and subsequently released VST and LFN could inhibit the formation of airway remodeling by preventing subepithelial fibrosis and angiogenesis. Meanwhile, MSCs reduced inflammatory cell infiltration and cytokine secretion to regulate the pathological microenvironment. Our results suggested that MSCs/PVLA could serve as a promising candidate to prevent disease exacerbations and treat refractory asthma.
科研通智能强力驱动
Strongly Powered by AbleSci AI